DOXIMITY INC-CLASS A (DOCS) Fundamental Analysis & Valuation

NYSE:DOCS • US26622P1075

Current stock price

23.3 USD
-0.43 (-1.81%)
At close:
23.3 USD
0 (0%)
After Hours:

This DOCS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. DOCS Profitability Analysis

1.1 Basic Checks

  • In the past year DOCS was profitable.
  • DOCS had a positive operating cash flow in the past year.
  • Each year in the past 5 years DOCS has been profitable.
  • Each year in the past 5 years DOCS had a positive operating cash flow.
DOCS Yearly Net Income VS EBIT VS OCF VS FCFDOCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

1.2 Ratios

  • DOCS's Return On Assets of 20.69% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
  • With an excellent Return On Equity value of 24.45%, DOCS belongs to the best of the industry, outperforming 94.29% of the companies in the same industry.
  • DOCS has a Return On Invested Capital of 19.48%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
  • DOCS had an Average Return On Invested Capital over the past 3 years of 14.17%. This is significantly above the industry average of 7.41%.
  • The last Return On Invested Capital (19.48%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 20.69%
ROE 24.45%
ROIC 19.48%
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
DOCS Yearly ROA, ROE, ROICDOCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • DOCS has a Profit Margin of 37.54%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
  • In the last couple of years the Profit Margin of DOCS has grown nicely.
  • DOCS has a better Operating Margin (37.44%) than 100.00% of its industry peers.
  • DOCS's Operating Margin has improved in the last couple of years.
  • The Gross Margin of DOCS (89.75%) is better than 97.14% of its industry peers.
  • In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
Industry RankSector Rank
OM 37.44%
PM (TTM) 37.54%
GM 89.75%
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
DOCS Yearly Profit, Operating, Gross MarginsDOCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. DOCS Health Analysis

2.1 Basic Checks

  • DOCS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, DOCS has more shares outstanding
  • DOCS has more shares outstanding than it did 5 years ago.
  • DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DOCS Yearly Shares OutstandingDOCS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
DOCS Yearly Total Debt VS Total AssetsDOCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • DOCS has an Altman-Z score of 16.93. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 16.93, DOCS belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
  • DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 16.93
ROIC/WACC1.94
WACC10.05%
DOCS Yearly LT Debt VS Equity VS FCFDOCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.3 Liquidity

  • DOCS has a Current Ratio of 6.63. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
  • DOCS's Current ratio of 6.63 is amongst the best of the industry. DOCS outperforms 91.43% of its industry peers.
  • A Quick Ratio of 6.63 indicates that DOCS has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 6.63, DOCS belongs to the best of the industry, outperforming 91.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.63
Quick Ratio 6.63
DOCS Yearly Current Assets VS Current LiabilitesDOCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. DOCS Growth Analysis

3.1 Past

  • DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.91%, which is quite impressive.
  • DOCS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 79.21% yearly.
  • The Revenue has grown by 15.92% in the past year. This is quite good.
  • DOCS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.42% yearly.
EPS 1Y (TTM)28.91%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%2.22%
Revenue 1Y (TTM)15.92%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%9.76%

3.2 Future

  • DOCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.76% yearly.
  • The Revenue is expected to grow by 11.82% on average over the next years. This is quite good.
EPS Next Y11.83%
EPS Next 2Y8.5%
EPS Next 3Y9.36%
EPS Next 5Y11.76%
Revenue Next Year13.71%
Revenue Next 2Y11.32%
Revenue Next 3Y10.74%
Revenue Next 5Y11.82%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DOCS Yearly Revenue VS EstimatesDOCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
DOCS Yearly EPS VS EstimatesDOCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. DOCS Valuation Analysis

4.1 Price/Earnings Ratio

  • DOCS is valuated correctly with a Price/Earnings ratio of 14.12.
  • Based on the Price/Earnings ratio, DOCS is valued cheaper than 82.86% of the companies in the same industry.
  • DOCS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.35.
  • Based on the Price/Forward Earnings ratio of 14.04, the valuation of DOCS can be described as correct.
  • DOCS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 77.14% of the companies in the same industry.
  • DOCS is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.61, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 14.12
Fwd PE 14.04
DOCS Price Earnings VS Forward Price EarningsDOCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • DOCS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 68.57% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, DOCS is valued a bit cheaper than the industry average as 77.14% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.01
EV/EBITDA 11.82
DOCS Per share dataDOCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

  • DOCS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)1.19
PEG (5Y)0.18
EPS Next 2Y8.5%
EPS Next 3Y9.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DOCS Dividend Analysis

5.1 Amount

  • No dividends for DOCS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DOCS Fundamentals: All Metrics, Ratios and Statistics

DOXIMITY INC-CLASS A

NYSE:DOCS (3/31/2026, 8:04:00 PM)

After market: 23.3 0 (0%)

23.3

-0.43 (-1.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)02-05
Earnings (Next)05-13
Inst Owners92.84%
Inst Owner Change1.98%
Ins Owners2.17%
Ins Owner Change0.22%
Market Cap4.30B
Revenue(TTM)637.78M
Net Income(TTM)239.40M
Analysts81.38
Price Target41.59 (78.5%)
Short Float %9.81%
Short Ratio3.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.81%
Min EPS beat(2)1.21%
Max EPS beat(2)16.41%
EPS beat(4)4
Avg EPS beat(4)17.96%
Min EPS beat(4)1.21%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)20.77%
EPS beat(12)12
Avg EPS beat(12)20.67%
EPS beat(16)16
Avg EPS beat(16)21.74%
Revenue beat(2)1
Avg Revenue beat(2)2.2%
Min Revenue beat(2)-0.43%
Max Revenue beat(2)4.82%
Revenue beat(4)3
Avg Revenue beat(4)2.07%
Min Revenue beat(4)-0.43%
Max Revenue beat(4)4.82%
Revenue beat(8)6
Avg Revenue beat(8)3.12%
Revenue beat(12)8
Avg Revenue beat(12)2.38%
Revenue beat(16)11
Avg Revenue beat(16)1.96%
PT rev (1m)-6.01%
PT rev (3m)-40.3%
EPS NQ rev (1m)-2.37%
EPS NQ rev (3m)-13.06%
EPS NY rev (1m)-1.99%
EPS NY rev (3m)-2.09%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-4.21%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.3%
Valuation
Industry RankSector Rank
PE 14.12
Fwd PE 14.04
P/S 6.75
P/FCF 14.01
P/OCF 13.64
P/B 4.39
P/tB 5.02
EV/EBITDA 11.82
EPS(TTM)1.65
EY7.08%
EPS(NY)1.66
Fwd EY7.12%
FCF(TTM)1.66
FCFY7.14%
OCF(TTM)1.71
OCFY7.33%
SpS3.45
BVpS5.3
TBVpS4.64
PEG (NY)1.19
PEG (5Y)0.18
Graham Number14.03
Profitability
Industry RankSector Rank
ROA 20.69%
ROE 24.45%
ROCE 23.71%
ROIC 19.48%
ROICexc 72.13%
ROICexgc 130.98%
OM 37.44%
PM (TTM) 37.54%
GM 89.75%
FCFM 48.17%
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 62.82%
Cap/Sales 1.29%
Interest Coverage 250
Cash Conversion 125.24%
Profit Quality 128.33%
Current Ratio 6.63
Quick Ratio 6.63
Altman-Z 16.93
F-Score7
WACC10.05%
ROIC/WACC1.94
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)28.91%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%2.22%
EPS Next Y11.83%
EPS Next 2Y8.5%
EPS Next 3Y9.36%
EPS Next 5Y11.76%
Revenue 1Y (TTM)15.92%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%9.76%
Revenue Next Year13.71%
Revenue Next 2Y11.32%
Revenue Next 3Y10.74%
Revenue Next 5Y11.82%
EBIT growth 1Y6.94%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year17.91%
EBIT Next 3Y11.16%
EBIT Next 5Y12.86%
FCF growth 1Y90.12%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y89.16%
OCF growth 3Y29.24%
OCF growth 5Y59.83%

DOXIMITY INC-CLASS A / DOCS Fundamental Analysis FAQ

What is the fundamental rating for DOCS stock?

ChartMill assigns a fundamental rating of 8 / 10 to DOCS.


What is the valuation status for DOCS stock?

ChartMill assigns a valuation rating of 6 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.


Can you provide the profitability details for DOXIMITY INC-CLASS A?

DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.


What is the valuation of DOXIMITY INC-CLASS A based on its PE and PB ratios?

The Price/Earnings (PE) ratio for DOXIMITY INC-CLASS A (DOCS) is 14.12 and the Price/Book (PB) ratio is 4.39.